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Fluoroquinolone-resistant  Campylobacter jejuni has been
observed worldwide and is now being seen in the United
States. Among patients in our health-care system in Pennsylva-
nia, fluoroquinolone-resistant C. jejuni were not observed from
1982 to 1992; however, resistance increased to 40.5% in 2001.
Resistance to erythromycin remains at a low level (<5%).
ampylobacter jejuni is the most common cause of bacte-
rial gastroenteritis in the United States, where an esti-
mated 2.5 million cases occur each year (1). Campylobacter
enteritis is primarily a foodborne illness; poultry is the major
source for human infection (1). Most campylobacter infections
need not be treated with antimicrobial agents; however, fluoro-
quinolones have been commonly used to treat serious Campy-
lobacter infections and are also used as empiric therapy for
travelers’ diarrhea (2).
Fluoroquinolone-resistant C. jejuni was recognized during
the late 1980s in Europe, where researchers suggested that
such resistance was due, in part, to acquisition of fluoroqui-
nolone-resistant strains from animal sources (3). Smith and
colleagues recently reported fluoroquinolone-resistant C.
jejuni in Minnesota and found that, from 1992 to 1998, fluoro-
quinolone resistance increased from 1.3% to 10.2% (4).
Recent data from the National Antimicrobial Resistance Mon-
itoring System (NARMS) show that 14.2% of isolates submit-
ted to the Centers for Disease Control and Prevention in 2000
were fluoroquinolone resistant (5). We have examined fluoro-
quinolone resistance and erythromycin resistance in C. jejuni
isolated from patients seen at our institution since 1982. Previ-
ously we reported that fluoroquinolone resistance was not
observed in isolates from 1982 to 1992 (6). In contrast to lim-
ited national data, we have observed a dramatic increase in flu-
oroquinolone resistance in C. jejuni since the mid-1990s.
The Study
The population we tested included patients treated by phy-
sicians within the University of Pennsylvania Health System,
which encompasses several Philadelphia-area hospitals. Most
isolates were from outpatients seen at the Hospital of the Uni-
versity of Pennsylvania or the Presbyterian Medical Center;
both serve the University of Pennsylvania community and
populations living in west Philadelphia. Stool samples were
collected as part of the routine evaluation of patients with diar-
rheal illness and sent in Cary-Blair transport medium to the
Clinical Microbiology Laboratory at the Hospital of the Uni-
versity of Pennsylvania for processing. Campylobacter organ-
isms were isolated and identified to species by using published
methods (7). Only C. jejuni subsp. jejuni were included in this
study. Each isolate tested represents a single patient. 
From 1995 through 2001, 404 patient isolates were
obtained from routine stool cultures; 297 (73.5%) were avail-
able for susceptibility testing. The ratio of males to females
was 1.15:1. The age distribution was nearly identical for both
sexes (males: median 33 yrs, mean 35 yrs [range 1–86 yrs];
females: medium 33 yrs; mean 36 yrs [range 8–95 yrs]). Iso-
lates were stored at –70°C and subcultured at least once before
testing. Susceptibility to ciprofloxacin and erythromycin was
determined with the E-test (AB Biodisk, Solna, Sweden)
method. Organisms were tested on Mueller-Hinton blood agar
medium and incubated at 37°C in microaerobic conditions.
The breakpoints used for resistance were >4 µg/mL for ciprof-
loxacin and >8 µg/mL for erythromycin (5). Flagellin gene
typing (Fla typing) was performed by using modified consen-
sus primers, described by Wassenaar and Newell (8), and
digested with DdeI as previously described (9).
As reported previously, fluoroquinolone-resistant C. jejuni
were not detected among 142 patient isolates tested from 1982
to 1992 at our institution (6). Erythromycin resistance was
2.0% overall from 1982 to 1992. Two hundred and ninety-
seven patient isolates were tested between 1995 and 2001 for
susceptibility to ciprofloxacin and erythromycin. Resistance
rates ranged from as low as 8.3% in 1996 to 40.5% in 2001
(Figure 1). In contrast, erythromycin resistance fluctuated
between 0% and 5% during the same period; in 2001 erythro-
mycin resistance was 3.5%. When all isolates tested during the
study period are considered, 28.9% of isolates were resistant in
the first calendar year quarter, 19.7% in the second quarter,
20% in the third quarter, and 19.2% in the fourth quarter. How-
ever, resistance isolates were more frequent beginning in
October 2000 and extending through April 2001 (Figure 2). 
Figure 3 shows the ciprofloxacin MIC distribution of iso-
lates from 1995 to 2001. A clear bimodal distribution of MICs
exists, with 96% of susceptible isolates with MICs <0.5 µg/
mL; except for one isolate, all resistant isolates had MICs >32
µg/mL. 
We used molecular typing by restriction fragment length
polymorphism analysis of Campylobacter flaA to determine
whether certain Fla types were associated with fluoroqui-
nolone resistance. Twenty-nine different Fla types occurred
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among the population of isolates. For strains where there were
at least four isolates represented in the type (Fla types 1, 7, 9,
10, 13, 15, 16, 25, 33, 44, 48, 49, 53, 57, 80, 86), the propor-
tion of resistant to susceptible isolates was no more than 0.25
and ranged from 0.07 to 0.25. None of the Fla types were spe-
cifically associated with fluoroquinolone resistance. 
Conclusions
We have observed a dramatic increase in fluoroquinolone-
resistant C. jejuni in patients treated within our health system
from 1995 to 2001 with a resistance rate of 40.5% in 2001. In
contrast, erythromycin-resistant C. jejuni has remained at a
low rate (<5%) for nearly 20 years. Before 1992, fluoroqui-
nolone-resistant C. jejuni had not been detected at our institu-
tion (6). Whether fluoroquinolone resistance emerged during
1993–1994 is unknown because isolates from that period were
not available. Similarly, a survey of isolates from 19 U.S.
counties in 1989 and 1990 did not find any fluoroquinolone-
resistant  C. jejuni (1). From 1997 through 2000, NARMS
reported 13%, 13%, 18 %, and 14% fluoroquinolone-resistant
C. jejuni, respectively (5). Erythromycin-resistant C. jejuni
occurred in 8%, 3%, 2%, and 1% of isolates from 1997 to
2000 among isolates tested by NARMS; our data parallels
these national data (5). The distribution of ciprofloxacin MICs
among C. jejuni from our survey also parallels NARMS data
between 1997 and 2000 (5). Fluoroquinolone-resistant isolates
exhibited high-level resistance with MICs >32 µg/mL.
The risk factors for acquiring fluoroquinolone-resistant C.
jejuni in the United States have not been defined; however,
foreign travel was identified by Smith and colleagues as an
important risk factor (for 75% of fluoroquinolone-resistant C.
jejuni) in Minnesota residents (4). Other, unidentified factors
were important, however, since the rest of infections were
domestically acquired.  Use of a fluoroquinolone within the
month before the collection of the stool sample was also iden-
tified as a potential risk factor (4). The increase in fluoroqui-
nolone-resistant  C. jejuni from 1996 through 1998 was
temporally associated with the licensure of fluroquinolones for
use in poultry in the United States (4). Several studies from
European colleagues noted this temporal relationship between
use of fluoroquinolones in animals and resistance among
human isolates in the 1980s (3).
The reasons for such a dramatic increase in fluoroqui-
nolone-resistant C. jejuni in our population are unknown. We
examined the connection between seasonality and isolation of
fluoroquinolone-resistant C. jejuni. We did observe increasing
rates of resistance for several quarters during the last 2-year
survey period. Whether this increase is indicative of foreign
travel patterns by our patients is unknown. Future studies
should focus on identifying the factors for acquisition of fluo-
roquinolone-resistant C. jejuni as well as the clinical implica-
tions of infection with such strains. Some evidence suggests
that infection with fluoroquinolone-resistant C. jejuni results
in prolonged illness. The duration of diarrhea among patients
treated with a fluoroquinolone in the Minnesota study was sig-
Figure 1. Trends in erythromycin and ciprofloxacin resistance in
Campylobacter jejuni, Philadelphia, 1982–2001. Number of isolates
tested: 1982–92 (n=142), 1995 (n=24), 1996 (n=48), 1997 (n=61), 1998
(n=37), 1999 (n=22), 2000 (n=48), and 2001 (n=47).
Figure 2. Fluoroquinolone-resistant Campylobacter, by quarter, 2000–
2001. Number of isolates tested for each quarter: Q1: 13, Q2: 13, Q3:
22, Q4: 10, Q5: 16, Q6: 15, Q7: 12, Q8: 14. 
Figure 3. Distribution of ciprofloxacin MICs in Campylobacter jejuni,
1995–2001.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1503
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nificantly longer if the patient had a fluoroquinolone-resistant
infection (median 10 days) versus a fluoroquinolone-suscepti-
ble infection (median 7 days)(4). Based on national trends and
our own local data, erythromycin continues to be the drug of
choice for treating Campylobacter gastroenteritis.
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